Research
Red Yeast Rice (Monascus purpureus)
76 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Monacolin K supplementation in patients with hypercholesterolemia: A systematic review of clinical trials.
Systematic review of 12 randomized-controlled-trials with 769 participants examining the effect and safety of monacolin K supplementation on blood cholesterol levels. Monacolin K showed a beneficial effect on LDL and total cholesterol levels, though some studies reported adverse side effects. Routine monitoring is suggested for patients treated with monacolin K.
Safety and Efficacy of the Consumption of the Nutraceutical "Red Yeast Rice Extract" for the Reduction of Hypercholesterolemia in Humans: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of 14 double-blinded clinical trials on red yeast rice extract for hypercholesterolemia. RYR extract significantly reduced total cholesterol and LDL-C without increasing life-threatening side effects.
Associations between the use of red yeast rice preparations and adverse health outcomes: An umbrella review of meta-analyses of randomized controlled trials.
Umbrella review of meta-analyses evaluating the associations between red yeast rice preparations and adverse health outcomes. The review included 15 meta-analyses with 186 randomized controlled trials. It found that 10 associations indicated a protective effect, 5 indicated increased risk related to uric acid and liver enzymes, and 46 showed no significant difference. The credibility of the evidence was generally low.
Impact of red yeast rice supplementation on lipid profile: a systematic review and meta-analysis of randomized-controlled trials.
Systematic review and meta-analysis of RCTs evaluating the effects of red yeast rice supplementation on lipid profiles. RYR significantly decreased total cholesterol, triglycerides, and LDL-C, and increased HDL-C, particularly effective in individuals with dyslipidemia.
Comparing the effectiveness of Chinese patent medicines containing red yeast rice on hyperlipidaemia: A network meta-analysis of randomized controlled trials.
Network meta-analysis of 47 randomized controlled trials involving 4824 subjects evaluated the effectiveness of Chinese patent medicines containing red yeast rice for hyperlipidaemia. Xuezhikang was most effective in reducing total cholesterol and low-density lipoprotein cholesterol levels, while Zhibituo was most effective for controlling triglyceride and high-density lipoprotein cholesterol levels.
Efficacy of red yeast rice extract on myocardial infarction patients with borderline hypercholesterolemia: A meta-analysis of randomized controlled trials.
Meta-analysis of seven studies with 10,699 myocardial infarction patients with borderline hypercholesterolemia. Red yeast rice extract (1,200 mg/day) reduced nonfatal MI, revascularization, and sudden death, and improved lipid profiles by lowering LDL, TC, TG, and increasing HDL levels.
Promotion of Bone Formation by Red Yeast Rice in Experimental Animals: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of 11 animal studies evaluating the effects of red yeast rice on bone formation. Results showed significant improvements in bone mineral density, osteoblast proliferation, and alkaline phosphatase expression, suggesting potential benefits for osteoporosis treatment.
Safety of red yeast rice supplementation: A systematic review and meta‐analysis of randomized controlled trials
Systematic review and meta-analysis of 53 RCTs with 8535 subjects assessing the safety of red yeast rice (RYR) supplementation. Monacolin K administration was not associated with increased risk of musculoskeletal disorders and showed reduced risk of non-musculoskeletal adverse events and serious adverse events compared to control.
Original Research: The Effects of Red Yeast Rice Supplementation on Cholesterol Levels in Adults.
This state-of-the-science review extends a previous meta-analysis to explore the effectiveness and safety of red yeast rice (RYR) supplementation in treating dyslipidemic adults. The review included 15 articles, with significant reductions in LDL and total cholesterol levels observed in all trials. No significant changes in liver and kidney function or creatine kinase levels were noted. Despite positive findings, further research is needed to support RYR supplementation recommendations.
The effects of red yeast rice dietary supplement on blood pressure, lipid profile, and C-reactive protein in hypertension: A systematic review.
Systematic review of 21 trials with 4558 patients evaluating red yeast rice (RYR) for hypertension. RYR plus conventional therapy significantly lowered total cholesterol, LDL-C, and CRP but had no significant effect on systolic BP, diastolic BP, triglycerides, and HDL-C compared to placebo. RYR plus statins was more effective in lowering BP, TC, TG, and LDL-C compared to statins alone. No serious adverse events were reported.
The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of randomized controlled trials assessing the effects of a nutraceutical combination (NComb) on plasma lipids and glucose levels. NComb, comprising red yeast rice, berberine, policosanol, astaxanthin, coenzyme Q10, and folic acid, significantly improved total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and glucose levels.
Systematic review of red yeast rice compared with simvastatin in dyslipidaemia.
Systematic review of 10 RCTs involving 905 Chinese subjects with dyslipidaemia comparing red yeast rice and simvastatin. No statistically significant difference was found in lipid-lowering effects between the two treatments.
A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.
Meta-analysis of 13 randomized, placebo-controlled trials with 804 participants assessing red yeast rice for dyslipidemia. Red yeast rice significantly lowered serum total cholesterol, triglycerides, and LDL-C, but had no significant effect on HDL-C. No serious side effects were reported.
Chinese herbal medicines for hypercholesterolemia.
Meta-analysis of 22 randomized trials with 2130 participants assessing Chinese herbal medicines for hypercholesterolemia. Xuezhikang showed a significant cholesterol-lowering effect compared to inositol nicotinate. The risk of bias in included trials was high or unclear.
Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS).
Post-hoc subgroup analysis of a randomized, double-blinded, placebo-controlled trial assessing the effects of Xuezhikang on blood pressure in 2704 hypertensive patients with previous myocardial infarction over 4.5 years. The study found no significant differences in blood pressure changes between Xuezhikang and placebo groups.
Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
RCT of 1530 elderly hypertensive patients with previous myocardial infarction comparing Xuezhikang to placebo over 4.5 years. Xuezhikang significantly reduced coronary events by 38.2% and CHD death by 29.2%, demonstrating its effectiveness in reducing cardiovascular events and all-cause mortality.
Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.
Multicenter RCT of nearly 5,000 Chinese patients with previous myocardial infarction, comparing Xuezhikang (XZK) to placebo over 4.5 years. XZK significantly decreased major coronary events, CV and total mortality, and improved lipoprotein profiles.
Low Dose Monacolin K Combined with Coenzyme Q10, Grape Seed, and Olive Leaf Extracts Lowers LDL Cholesterol in Patients with Mild Dyslipidemia: A Multicenter, Randomized Controlled Trial.
RCT assessing the lipid-lowering activity and safety of a dietary supplement containing monacolin K, coenzyme Q10, grape seed, and olive leaf extracts in 105 patients with mild hypercholesterolemia. LDL-C decreased by 26.46% with 10 mg and by 16.77% with 3 mg of monacolin K. No severe adverse events occurred.
Evaluation of the effect of a dietary supplementation with a red yeast rice and fish oil-containing nutraceutical on lipid pattern, high sensitivity C-reactive protein, and endothelial function in moderately hypercholesterolaemic subjects: a double-blind, placebo-controlled, randomized clinical tria
Double-blind, randomized, placebo-controlled clinical trial testing 8 weeks of supplementation with red yeast rice and PUFAs in moderately hypercholesterolaemic subjects. The supplement significantly improved LDL-C, TC, apoB, hsCRP, and endothelial function.
Effectiveness and safety of red yeast rice predominated by monacolin K β-hydroxy acid form for hyperlipidemia treatment and management.
RCT assessing the lipid-lowering activity and safety of a dietary supplement containing monacolin K β-hydroxy acid form (MKA) in 117 subjects with dyslipidemia. MKA significantly decreased LDL-C, TC, and non-HDL-C, with weak evidence of triglyceride reduction and HDL-C increment. No severe adverse events were reported.
Effect of "Natural Polypill", Xuezhikang on Serum Cholesterol Metabolism Markers in Early Menopausal Women with Hypercholesterolemia.
RCT of 90 early menopausal women with hypercholesterolemia comparing Xuezhikang to atorvastatin over 8 weeks. Both treatments significantly reduced total cholesterol, triglycerides, and low-density cholesterol. Xuezhikang showed more comprehensive effects on cholesterol synthesis markers compared to atorvastatin.
A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study).
A randomized, double-blind, placebo-controlled clinical trial tested the effects of a nutraceutical combination containing phytosterols, red yeast rice, niacin, and policosanols on lipid profiles in 88 moderately hypercholesterolemic subjects. The nutraceutical significantly reduced LDL-C, TC, non-HDL-C, ApoB, TC/HDL-C, and LDL-C/HDL-C ratios compared to placebo, indicating a positive effect on heart health.
Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis.
Systematic review and meta-analysis of 20 studies evaluating red yeast rice (RYR) for LDL cholesterol reduction. RYR significantly lowered LDL cholesterol by 1.02 mmol/L compared to placebo, with a safety profile similar to statins. However, the quality of safety assessment was low in most studies.
Combined treatment with Dif1stat and diet reduce plasma lipid indicators of moderate hypercholesterolemia more effectively than diet alone: a randomized trial in parallel groups.
An open-labeled randomized trial studied the effects of Dif1stat (Monascus purpureus-Linear aliphatic alcohols-Niacin) combined with diet on primary moderate hypercholesterolemia over 8 months. Group B, receiving Dif1stat and diet, showed significant reductions in cholesterol and triglycerides compared to diet alone, indicating an anti-atherogenic effect.
A Combination ofStrains CECT7527, CECT7528, and CECT7529 Plus Monacolin K Reduces Blood Cholesterol: Results from a Randomized, Double-Blind, Placebo-Controlled Study.
A 12-week randomized, double-blind, placebo-controlled trial evaluated the efficacy of red yeast rice containing 10 mg of monacolin K combined with three probiotic strains in 39 adults with high cholesterol. The intervention group showed a significant reduction in LDL and total cholesterol compared to placebo, with no adverse effects reported.
Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study).
This randomized, double-blind, placebo-controlled study evaluated the effects of a nutraceutical combination (BB536, red yeast rice extract) on oxysterol levels in subjects with moderate hypercholesterolemia. The study found that 27-OHC levels were significantly reduced by 10.4% in the nutraceutical group, while other oxysterol levels remained unchanged.
Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial.
A multicenter randomized trial with 18 patients with mild dyslipidemia comparing low dose red yeast rice (200 mg/day) containing 2 mg monacolin K to diet therapy alone for 8 weeks. The red yeast rice group showed significant reductions in low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and blood pressure without severe adverse effects.
The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension.
RCT of 131 subjects with pre-hypertension comparing a nutraceutical compound (red yeast rice, berberine, coenzyme Q10, folic acid, and chrome) to diet alone for 3 months. The treatment group showed significant reductions in total cholesterol, LDL cholesterol, triglycerides, and glucose levels, with increased HDL cholesterol, indicating improved lipid and metabolic profiles.
Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial.
Pilot randomized trial evaluating the effects of two nutraceutical combinations on endothelial function, lipid profile, and glucose metabolism in 50 dyslipidemic subjects. Both combinations improved lipid profiles, with one combination showing significant improvement in endothelial function and cholesterol lowering.
A Randomized Clinical Efficacy Trial of Red Yeast Rice (Monascus pilosus) Against Hyperlipidemia.
RCT examining the efficacy of monacolin K-rich and GABA-rich red yeast rice (Monascus pilosus) on hyperlipidemia. Monacolin K-rich RYR significantly reduced serum TC and LDL-C levels compared to baseline and other groups, while GABA-rich RYR showed non-significant reduction on serum triglyceride. Two subjects reported elevated liver enzymes.
Efficacy and tolerability of a nutraceutical combination of red yeast rice, guggulipid, and chromium picolinate evaluated in a randomized, placebo-controlled, double-blind study.
RCT evaluating the efficacy and tolerability of NutraforChol, a nutraceutical containing red yeast rice, guggulipid, and chromium picolinate, in subjects with mild dyslipidemia. The study found significant reductions in total cholesterol and LDL levels after 8 weeks, with no significant changes in renal and liver function parameters.
Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment.
This randomized, prospective, parallel-group, single-blind study evaluated the efficacy of low-dose statin plus ezetimibe or low-dose statin plus nutraceutical (Armolipid Plus containing red yeast rice, policosanol, and berberine) in achieving target LDL-C levels in coronary artery disease patients intolerant to high-dose statin. 66% of patients treated with LDS + EZE and 62% with LDS + ALP achieved target LDL-C after 3 months, with 92% reaching target at 6 months. The combination was effective and well-tolerated.
Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial.
RCT of 80 Caucasian patients with low cardiovascular risk comparing a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols to placebo. The combination improved lipid profile and markers of endothelial damage both at fasting and after an oral fat load.
Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial).
RCT comparing low-dose statin therapy versus combined therapy of low-dose statin plus Armolipid Plus in 100 high-risk patients with coronary artery disease and high-dose statin intolerance. The Armolipid Plus group showed a significantly greater reduction in LDL-C and total cholesterol, with 70% achieving the therapeutic target.
Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial.
This double-blind, placebo-controlled randomized clinical trial studied the effects of a nutraceutical containing red yeast rice, phytosterols, and L-tyrosol on lipid profile, blood pressure, and cardiovascular risk in 60 patients with polygenic hypercholesterolemia. The nutraceutical improved total cholesterol, LDL-C, hepatic steatosis index, ALT, AST, serum uric acid, systolic blood pressure, endothelial reactivity, and estimated 10-year cardiovascular risk score compared to placebo.
Red yeast rice induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: a single center randomized pilot trial.
RCT comparing red yeast rice to simvastatin in 60 dyslipidemic patients with low to moderate cardiovascular risk over 4 weeks. Red yeast rice induced less muscle fatigue and maintained physical activity levels better than simvastatin, with similar lipid-lowering effects.
ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia.
This multicenter, double-blind RCT studied the effects of a nutritional supplement containing red yeast rice, grape-seed, niacinamide, and folic acid (RYR-NS) on LDL-C levels in 191 statin-free subjects with newly-diagnosed hyperlipidemia. The RYR-NS group showed a significant reduction in LDL-C and non-HDL-C levels compared to placebo after 12 weeks, with no safety issues observed.
Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention.
RCT of 142 nonstatin-treated participants with hypercholesterolemia comparing 3 mg monacolin K from red yeast rice and 200 μg folic acid to placebo. The supplement group showed significant reductions in LDL-C, total cholesterol, and homocysteine after 12 weeks, with no significant changes in the placebo group.
No additional cholesterol-lowering effect observed in the combined treatment of red yeast rice and Lactobacillus casei in hyperlipidemic patients: A double-blind randomized controlled clinical trial.
Double-blind RCT evaluating the cholesterol-lowering effect of combining red yeast rice and Lactobacillus casei in 60 hyperlipidemic patients. No additional cholesterol-lowering effect was observed with the combination compared to red yeast rice alone. A significant difference in diastolic pressure was noted, potentially linked to L. casei.
Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study.
Multicenter open study comparing the effects of a combined nutraceutical containing red yeast rice and PUFAs versus phytosterols in subjects with primary polygenic hypercholesterolemia and metabolic syndrome. The combined nutraceutical group showed a significant decrease in total cholesterol, LDL-C, triglycerides, and non-HDL-C compared to baseline and the phytosterol group.
Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease.
A single-blind, single-center, randomized trial compared the efficacy and tolerability of Armolipid Plus (a combination of nutraceuticals) versus ezetimibe in statin-intolerant patients with dyslipidemia and coronary heart disease. After 3 months, 14 patients in the nutraceutical group achieved their therapeutic target, whereas none in the ezetimibe group did. At 1-year follow-up, 72.5% of the combined therapy group and 100% of the nutraceutical group reached the therapeutic goal. No significant adverse effects were reported.
Nutraceuticals for Serum Lipid and Blood Pressure Control in Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk.
RCT of 66 patients with hypertension and hypercholesterolemia testing a nutraceutical compound containing red yeast rice, policosanol, berberine, folic acid, and coenzyme Q10. The treatment group showed significant reductions in systolic and pulse pressure, total cholesterol, LDL-C, and triglycerides, with no changes in HDL-C.
Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trial.
Double blind placebo controlled randomized trial of 50 persons with metabolic syndrome testing a supplement combining red yeast rice and olive extract. The intervention group showed significant reductions in LDL cholesterol, total cholesterol, apolipoprotein B, triglycerides, and oxidized LDL, as well as decreased systolic and diastolic blood pressure compared to the control group.
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Double-blind randomized cross-over trial comparing two nutraceutical combinations in dyslipidemic patients. Combination B, which includes Morus alba, showed greater reductions in LDL cholesterol, glycated hemoglobin, fasting glucose, and insulin levels compared to Combination A.
A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters.
A double-blind, placebo-controlled RCT with 134 dislipidemic patients evaluated the effects of a nutraceutical combination of red yeast rice, Silybum marianum, and octasonol on lipid profile, endothelial, and inflammatory parameters. The combination improved total cholesterol, LDL cholesterol, and reduced various inflammatory markers compared to placebo.
Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.
RCT of 116 adults with dyslipidemia comparing placebo to Xuezhikang (XZK) 1200 or 2400 mg daily for 12 weeks. XZK significantly reduced non-HDL-C and LDL-C levels, with additional benefits on total cholesterol, apolipoprotein B, triglycerides, and HDL-C. XZK was safe and well tolerated.
Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial.
A multicenter randomized trial assessed the effects of Armolipid Plus, a supplement containing red yeast rice extract, policosanol, berberine, folic acid, coenzyme Q10, and asthaxantine, on cardiovascular biomarkers in 102 participants with moderate hypercholesterolemia. The supplement reduced LDL-c, ApoB-100, and cholesterol ratios while increasing ApoA1, and was associated with modest weight loss compared to placebo.
Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial.
RCT of 187 participants with statin intolerance comparing red yeast rice with and without phytosterols, alongside lifestyle changes. Phytosterols did not significantly improve LDL-C compared to placebo. Lifestyle changes led to greater LDL-C reduction and weight loss. Red yeast rice significantly decreased LDL-C, total cholesterol, triglycerides, and increased HDL cholesterol.
A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial.
RCT of a natural cholesterol-lowering supplement (NCLS) containing red yeast rice, policosanols, and artichoke leaf extracts in 100 volunteers with untreated moderate hypercholesterolemia. The supplement reduced LDL cholesterol and apolipoprotein B100 without affecting safety parameters over 16 weeks.
Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial.
Double blind placebo controlled randomized trial of red yeast rice (RYR) in 52 physicians and their spouses with high cholesterol. RYR significantly lowered LDL cholesterol by 36 mg/dL (22%) and total cholesterol by 37 mg/dL (15%) compared to placebo. No significant difference in side-effects or CK elevation was observed.
Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products.
The study compared the dissolution rate, physical state, and oral bioavailability of lovastatin in three red yeast rice (RYR) products to lovastatin tablets. Results showed that RYR products had a faster and higher dissolution rate, reduced crystallinity, and significantly improved oral bioavailability of lovastatin compared to lovastatin tablets.
Combined extractives of red yeast rice, bitter gourd, chlorella, soy protein, and licorice improve total cholesterol, low-density lipoprotein cholesterol, and triglyceride in subjects with metabolic syndrome.
Double-blinded RCT examining the effects of a plant-extractive compound on lipid profiles in subjects with metabolic syndrome. The compound, including red yeast rice, bitter gourd, chlorella, soy protein, and licorice, significantly reduced total cholesterol, low-density lipoprotein cholesterol, and triglycerides compared to placebo. It also reduced the proportion of subjects with hypertensive criteria.
A multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability).
This multicenter RCT evaluated the effects of nutraceutical drinks with and without red yeast rice (RYR) on cholesterol levels in 79 subjects. The drink containing RYR significantly reduced total and LDL cholesterol at 4 and 8 weeks, while the drink without RYR showed no change. The RYR drink was well-tolerated, with only one subject experiencing a headache.
Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial.
RCT of 62 statin-intolerant patients with dyslipidemia comparing red yeast rice to placebo over 24 weeks. Red yeast rice significantly decreased LDL cholesterol levels compared to placebo, without increasing CPK or pain levels.
Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial.
This randomized trial compared the lipid-lowering effects of an alternative regimen (lifestyle changes, red yeast rice, and fish oil) with simvastatin in 74 patients with hypercholesterolemia. Both groups showed significant reductions in LDL-C levels, with the alternative group also showing significant reductions in triglycerides and weight.
Does EFSA statement on Monacolin content of nutraceutical combinations impair their lipid lowering effect? The LopiGLIK experience
The study compares the cholesterol-lowering effects of Armolipid Plus® and LopiGLIK®, focusing on Monacolin-K, the active component of red yeast rice. Despite reducing Monacolin-K content to comply with EFSA guidelines, LopiGLIK® maintained its efficacy, suggesting other ingredients like Morus alba may enhance its effectiveness.
Safety and Efficacy of NC120 for Improving Lipid Profile: A Double Blind Randomized Controlled Trial.
Double blind randomized controlled trial comparing NC120, containing red yeast rice, guggulipid, and chromium picolinate, with placebo in subjects with hypercholesterolemia. NC120 significantly reduced total cholesterol and LDL-cholesterol but not triglycerides. Side effects were minor and comparable between groups.
Effects of a Novel Nutraceutical Combination (Aquilea Colesterol) on the Lipid Profile and Inflammatory Biomarkers: A Randomized Control Trial.
RCT evaluating the effects of a nutraceutical combination (Aquilea Colesterol) containing phytosterols, red yeast rice, and hydroxytyrosol on lipid profile and inflammatory biomarkers in individuals with moderate hypercholesterolemia. The nutraceutical significantly reduced total cholesterol, LDL-c, apolipoprotein B, and hs-CRP compared to placebo over one and three months.
NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial.
This randomized cross-over trial investigated the effects of a nutraceutical combination containing red yeast rice and berberine on lipid profile, PCSK9, subclinical inflammation, and arterial stiffness in 30 ART-treated HIV-infected patients. The nutraceutical significantly reduced total cholesterol, LDL-C, PCSK9 levels, and hs-CRP, and improved arterial stiffness without significant side effects.
The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk.
RCT investigating the efficacy and safety of a nutraceutical compound containing high doses of monacolin K in improving lipid profile and glucose metabolism in hypertensive and hypercholesterolemic subjects. The treatment group showed significant reductions in total cholesterol, LDL cholesterol, and blood glucose compared to the control group.
Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia.
An observational study evaluated the efficacy, tolerance, and safety of Cholesfytol, a combination of red yeast rice and olive extract, in 642 hypercholesterolemic patients. The study found significant reductions in total cholesterol and LDL-C levels, with greater reductions in patients with higher baseline values. Minor side effects were reported by 13 patients, and 4 patients with antecedent SAMS reported myalgia.
A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial.
A double-blind, placebo-controlled, randomised trial with 49 patients with metabolic syndrome tested the effects of a red yeast rice-olive extract supplement. The supplement significantly reduced Lp-PLA by 7% and OxLDL by 20%, suggesting a potential reduced risk for cardiovascular disease.
Middle-Term Dietary Supplementation with Red Yeast Rice Plus Coenzyme Q10 Improves Lipid Pattern, Endothelial Reactivity and Arterial Stiffness in Moderately Hypercholesterolemic Subjects.
This double-blind, placebo-controlled RCT investigated the effects of red yeast rice plus Coenzyme Q10 supplementation on lipid patterns, endothelial reactivity, and arterial stiffness in 40 moderately hypercholesterolemic subjects. The treatment group showed significant improvements in LDL-cholesterol, endothelial reactivity, and arterial stiffness compared to placebo.
Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus.
RCT of 30 patients with moderate dyslipidemia and metabolic syndrome comparing Armolipid Plus to placebo and pravastatin. Armolipid Plus significantly reduced total and LDL cholesterol and increased HDL cholesterol, showing lipid-lowering activity comparable to pravastatin.
Relationship between adiponectin and leptin, and blood lipids in hyperlipidemia patients treated with red yeast rice.
RCT of 30 hyperlipidemia patients treated with red yeast rice capsules 600 mg twice a day for 8 weeks. Significant decreases in LDL-C and total cholesterol were observed, along with an increase in adiponectin. Adiponectin correlated positively with HDL-C, and leptin correlated negatively with TG.
Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects.
A crossover, double-blind, placebo-controlled RCT tested the effects of 10 mg monacolins from red yeast rice on lipid patterns, hs-CRP, and vascular remodeling biomarkers in 25 mildly hypercholesterolemic Italian subjects. Monacolins significantly improved total cholesterol, LDL cholesterol, non-HDL cholesterol, matrix metalloproteinases 2 and 9, and hs-CRP compared to placebo, with no significant differences in triglycerides, HDL cholesterol, and safety parameters.
Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study.
RCT of 45 subjects with untreated hypercholesterolaemia comparing a dietary supplement containing red yeast rice extract, policosanol, and artichoke leaf extract at two doses to placebo. Both doses significantly reduced LDL-cholesterol compared to placebo, with no additional benefit from the higher dose. No adverse effects on muscle, liver, or renal biomarkers were observed.
LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia.
Double-blind, randomized controlled trial of a dietary supplement containing red yeast rice, sugar cane-derived policosanols, and artichoke leaf extracts in 39 subjects with moderate hypercholesterolemia. The supplement reduced LDL-cholesterol by 21.4% and total cholesterol by 14.1% after 16 weeks, suggesting it may aid in managing mild to moderate hypercholesterolemia.
Nutraceuticals for blood pressure control in patients with high-normal or grade 1 hypertension.
RCT comparing two nutraceutical combinations in 30 patients with grade 1 hypertension. The combination including Orthosiphon stamineus significantly reduced mean 24-hour systolic and diastolic BP levels, while the combination without it did not show significant BP reduction.
HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study.
A randomized, double-blind, placebo-controlled study of 42 patients assessed the effect of red yeast rice (HypoCol) on plasma lipids over 16 weeks. The RYR group showed significant reductions in LDL-cholesterol (23.0%) and total cholesterol (15.5%) compared to placebo.
The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols.
Double-blind, randomized, placebo-controlled, cross-over trial in 40 hypercholesterolemic children evaluating a dietary supplement containing red yeast rice extract and policosanols. The supplement significantly reduced total cholesterol, LDL-C, and apolipoprotein B levels compared to placebo, with no adverse effects detected.
Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
RCT comparing the tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in 43 patients with previous statin intolerance due to myalgia. Red yeast rice was tolerated as well as pravastatin and achieved a comparable reduction in low-density lipoprotein cholesterol.
Effect of Red Yeast Rice on Cognitive Functioning in Schizophrenia: Data From a Pilot Study.
Pilot study of 35 schizophrenia outpatients receiving 200 mg/day red yeast rice for 12 weeks. Red yeast rice supplementation significantly improved cognitive functioning, specifically WCST 'perseverative errors' and phonemic fluency test, with small effect sizes. No significant changes in clinical symptoms or adverse effects were reported.
A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
Pilot study of a multi-ingredient supplement (MIS) featuring red yeast rice (RYR) and omega-3 fatty acids in 19 patients with hypercholesterolemia. The MIS significantly decreased total cholesterol and LDL levels. The addition of omega-3s decreased triglycerides in a subgroup, though not significantly. No side effects were reported.
Powdered red yeast rice and plant stanols and sterols to lower cholesterol.
Case series of 18 patients with hypercholesterolemia using a proprietary product combining red yeast rice and phytosterols. Significant reductions in total cholesterol (19%) and LDL cholesterol (33%) were observed after 6 weeks, with no significant side effects reported.
Statin intolerance: now a solved problem.
The paper discusses strategies for managing statin intolerance in hyperlipidemic patients, including lower and intermittent dosing of statins, alternate hypolipidemic drugs, and supplementation with red yeast rice, coenzyme Q10, and vitamin D.